Dr Mahboubeh Rahmani, MD | |
310 Cedar St, New Haven, CT 06510-3218 | |
(203) 737-2115 | |
Not Available |
Full Name | Dr Mahboubeh Rahmani |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 310 Cedar St, New Haven, Connecticut |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1043568298 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Dr Mahboubeh Rahmani, MD 310 Cedar St, New Haven, CT 06510-3218 Ph: (203) 737-2115 | Dr Mahboubeh Rahmani, MD 310 Cedar St, New Haven, CT 06510-3218 Ph: (203) 737-2115 |
News Archive
Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.
A new study recently published in the Journal of Thoracic and Cardiovascular Surgery questions whether patients with isolated moderate to severe mitral valve regurgitation should receive treatment in earlier stages instead of waiting until symptoms appear.
Breast cancer patients treated with anthracycline-based chemotherapy regimens may be at greater risk of neurocognitive problems than those given nonanthracycline regimens, indicate findings.
Scientists investigating the cancer-fighting properties of artesunate - a drug commonly used to treat malaria - have found early evidence that combining it with an existing cancer drug has the potential to make each drug more effective than when used alone. They also found that regular treatment breaks could improve success levels.
› Verified 9 days ago